Digital Look

Welcome to Digital Look++,
you are not logged in

AstraZeneca (AZN)

Pharma and Biotech

13,980.00p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
30-Sep-25	Q3	15,191.00	3,244.00	164.00¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-20	26,617.00	3,916.00	244.00¢	40.2	0.3	+137%	280.00¢	2.9%
31-Dec-21	37,417.00	(265.00)	8.00¢	1,454.4	n/a	-97%	287.00¢	2.5%
31-Dec-22	44,351.00	2,501.00	212.00¢	70.9	0.0	+2,550%	290.00¢	1.9%
31-Dec-23	45,811.00	6,899.00	726.00¢	19.6	0.1	+242%	290.00¢	2.0%
31-Dec-24	54,073.00	8,691.00	821.00¢	17.1	1.3	+13%	310.00¢	2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Year Ending	Revenue (£m)	Pre-tax (£m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
31-Dec-25	58,660.61	18,444.75	683.31p	20.6	1.8	+11%	241.91p	0.0%
31-Dec-26	62,194.14	20,588.48	766.89p	18.3	1.5	+12%	254.67p	0.0%
31-Dec-27	65,845.97	22,790.20	856.51p	16.4	1.4	+12%	265.37p	0.0%

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	41.01	15.96	321.31	0.07

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.